LeonaBio (LONA) investor relations material

Executive summary

• Focused on developing therapeutics for metastatic breast cancer and ALS, with lead assets lasofoxifene (Phase 3 ELAINE-3 trial) and brelgometon (Phase 2 planning).

• No approved products or revenue; operations funded by equity and warrant issuances, with $51.1M in cash and investments as of June 30, 2026.

• Net loss for the six months ended June 30, 2026 was $52.0M, up from $16.1M in the prior year period.

• Substantial doubt exists about ability to continue as a going concern beyond the next 12 months without additional capital.

• Recent board changes include three new directors and one retirement.

Financial highlights

• Research and development expenses rose 201% year-over-year to $24.0M for the six months ended June 30, 2026, mainly due to lasofoxifene program costs.

• General and administrative expenses increased 52% year-over-year to $13.5M for the six months ended June 30, 2026.

• Net loss for Q2 2026 was $19.0M ($0.80/share), compared to $7.0M in Q2 2025.

• Cash used in operating activities was $37.9M for the first half of 2026.

• Cash, cash equivalents, and investments totaled $51.1M as of June 30, 2026, down from $88.3M at year-end 2025.

Outlook and guidance

• Enrollment in the ELAINE-3 Phase 3 trial for lasofoxifene expected to complete in Q4 2026, with topline data in 2H 2027.

• Phase 2 trial for brelgometon in ALS to be planned after ELAINE-3 enrollment completion.

• Up to $146.2M in additional capital may be available upon exercise of warrants from the December 2025 financing.

• Current cash and investments may not fund operations for the next 12 months; additional capital will be required.